Navigation Links
Bionovo to Present Recent Findings of BN107 and BN108, Its Anticancer Agents, at the American Association of Cancer Research
Date:4/15/2008

EMERYVILLE, Calif., April 15 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI) will present findings on the mechanism of action of two of its anti-cancer agents BN107 and BN108 at the American Association of Cancer Research (AACR) being held at the San Diego Convention Center in San Diego, CA, April 12 - 16, 2008.

Bionovo's poster presentation will describe the pathway for cancer cell apoptosis (cell death) induced by BN107 and BN108. As explained by Dr. Emma Shtivelman, Director of Cancer Research at Bionovo, the ability of BN107 to induce death cancer cell death is distinct from that of BN108. BN107 induces apoptosis through the mitochondrial pathway. BN107 induces death only in estrogen receptor negative breast cancer cells. BN108 induces cancer cell death by rapid inactivation of both AKT and mTOR pathways in breast cancer cells, but not in normal cells.

"BN107 and BN108 mechanisms of action and unique selective properties are a result of some of the biological differences between cancer cells and normal cells as well as cancer cells' uniquely acquired functions," said Dr. Isaac Cohen, President and CEO of Bionovo. "We believe both drugs will result in better tolerability and better toxicity profile than conventional chemotherapy due to better target selectivity. Oral administration will provide availability for chronic treatment and will mark these new targeted compounds as promising investigational drugs."

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit: http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bionovo Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness
2. Louis Drapeau Joins Bionovos Board of Directors
3. George Butler Joins Bionovos Board of Directors
4. Bionovo to Present at Bank of Montreals 2007 Focus on Healthcare Conference
5. Bionovo Announces Third Quarter 2007 Financial Results
6. Bionovo Announces the Pricing of Public Offering of Shares of Common Stock
7. Bionovo to Present at the Biotechnology Industry Organization (BIO) Investor Forum
8. Bionovo Announces Proposed Public Offering of Common Stock
9. Bionovo to Present at A.G. Edwards 2nd Annual Emerging Growth Conference 2007
10. ARIUS presents new findings for anti-cancer antibody programs at AACR
11. Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , Dec. 1, 2016   SurePure, Inc. ... announced today that the Company has concluded an agreement ... right for a 90-day period to acquire units of ... of approximately USD 3.7 million.  Concurrently ... with Tamarack under which Tamarack will seek regulatory approvals ...
(Date:11/30/2016)... CLEVELAND , Nov. 30, 2016  GenomOncology today announced ... Vice President of Medical Affairs.  Dr. Coleman ... enhancing the company,s proprietary knowledge-enabled platform. The GenomOncology software suite ... of genetic sequencing data and clinical decision support, from quality ... , ...
(Date:11/30/2016)... 30, 2016  The Allen Institute for Cell ... first publicly available collection of gene edited, fluorescently ... key cellular structures with unprecedented clarity. Distributed through ... tools are a crucial first step toward visualizing ... what makes human cells healthy and what goes ...
(Date:11/30/2016)... , 30. November 2016   Merck ... heute die Unterzeichnung einer Reihe von Vereinbarungen ... wird Evotec AG Screeningleistungen für Mercks Palette ... Der Zugriff auf diese Bibliotheken in Kombination ... einen schnelleren Weg zur Ermittlung und Erforschung ...
Breaking Biology Technology:
(Date:6/9/2016)... an innovation leader in attendance control systems is proud to announce the introduction of ... make sure the right employees are actually signing in, and to even control the ... ... ... ...
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
(Date:6/2/2016)... , June 2, 2016 Perimeter ... Platforms, Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... market will generate revenues of $17.98 billion in 2016. ... DVTEL Inc, a leader in software and hardware technologies ...
Breaking Biology News(10 mins):